MetaCap

Elutia (ELUT) vs MiNK Therapeutics (INKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elutia (ELUT) has outperformed MiNK Therapeutics (INKT) over the past year, gaining 52.6% versus a loss of 24.1%. Over five years, ELUT leads with a -82.8% price change compared with -96.0% for INKT. MiNK Therapeutics is the larger company by market cap ($41.2 million vs $40.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELUT+52.56%INKT-24.05%
+113%+41%-31%
Nov 21, 20251 yearNov 20, 2026
ELUT-84.48%INKT-94.98%
+47%-28%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELUT versus INKT key metrics
MetricELUTINKT
Share price$0.9001$8.02
Market cap$39.96M$41.17M
1-day change+11.12%-6.85%
YTD return+29.88%-28.07%
1-year return+52.56%-24.05%
5-year return-82.76%-95.99%
EPS (TTM)$-0.68$-2.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$12.29M—
Revenue growth (YoY)-15.03%—
Net income (latest FY)$53.38M$-12.49M
Gross margin53.66%—
Operating margin-218.91%—
Net margin434.23%—
52-week high$1.39$16.93
52-week low$0.50$7.76
Distance from 52-week high-35.01%-52.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+455.49%+386.28%
Average volume185.17K15.74K
Shares outstanding44.40M5.13M
Employees2515
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELUT has outperformed INKT by 76.6 percentage points over the past year.

About Elutia

ELUT stock →

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees

About MiNK Therapeutics

INKT stock →

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees

ELUT vs INKT FAQ

Which is bigger, Elutia or MiNK Therapeutics?

MiNK Therapeutics (INKT) is larger, with a market capitalization of $41.17M compared with $39.96M for Elutia (ELUT).

Which stock has performed better over the past year, ELUT or INKT?

ELUT returned +52.56% over the past 12 months, compared with -24.05% for INKT (price return, excluding dividends). Past performance does not predict future results.

Are Elutia and MiNK Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons